Interventional Radiology Imaging

Which Imaging Study Best Stages Newly Diagnosed High-Risk Melanoma in Adults?

·
Which Imaging Study Best Stages Newly Diagnosed High-Risk Melanoma in Adults?

A 58-year-old patient’s wide local excision and sentinel lymph node biopsy results have just arrived. The primary cutaneous melanoma on their back was intermediate thickness, but the pathology report confirms two critical findings: microscopic satellites around the primary lesion and a positive sentinel lymph node in the axilla. The patient is otherwise asymptomatic. You now face the crucial decision of systemic staging to detect or rule out distant disease before finalizing the treatment plan with the oncology team. This article provides a focused, evidence-based workflow for this specific clinical scenario, explaining why the American College of Radiology (ACR) finds one imaging modality to be the most effective first step. For this presentation, `FDG-PET/CT whole body` is rated Usually appropriate.

Who Fits This Clinical Scenario for Melanoma Staging?

This guidance is specifically for an adult patient with a newly diagnosed cutaneous or muco-cutaneous melanoma who has evidence of a higher risk for metastatic spread. The key inclusion criteria are the new diagnosis combined with at least one of the following findings:

  • Microscopic satellites or in-transit metastases identified on the primary lesion biopsy or excision specimen.
  • Positive regional lymph nodes confirmed by sentinel lymph node biopsy (SLNB) or a wider lymph node dissection.
  • Suspected regional lymph node involvement based on clinical signs or symptoms, such as palpable or matted lymph nodes on physical examination.

This workflow is distinct from other common melanoma presentations. It does not apply to patients with thin, low-risk primary melanomas who have no clinical or pathologic evidence of regional spread; those patients typically do not require systemic imaging for initial staging. It is also not intended for routine surveillance in patients who have already completed initial staging and treatment and are now asymptomatic. Finally, this guidance is for initial staging, not for evaluating treatment response in a patient with already-known distant metastatic disease, which follows a different set of clinical considerations.

What Diagnoses Are You Working Up in This High-Risk Melanoma Scenario?

In this context, the “differential diagnosis” is less about identifying the primary disease—which is known—and more about determining the extent of its spread. The purpose of staging imaging is to accurately map the disease burden, which is the single most important factor in determining prognosis and selecting appropriate therapy, from surgery and radiation to systemic immunotherapy or targeted therapy. The primary questions you are trying to answer involve the presence of occult disease in key locations.

Regional Nodal Metastases: The primary concern is identifying additional nodal disease beyond what was found on the sentinel node biopsy. This includes non-sentinel nodes within the same basin, nodes in adjacent basins, or in-transit metastases along the lymphatic channels between the primary tumor and the regional lymph node basin. Identifying this burden is critical for planning potential complete lymph node dissection or regional radiation therapy.

Distant Organ Metastases: Melanoma has a predilection for spreading to distant organs, and these metastases are often clinically silent in early stages. The most common sites include the lungs, liver, and adrenal glands. Detecting visceral metastases immediately upstages the patient (to Stage IV) and fundamentally changes the treatment paradigm to a systemic approach.

Distant Non-Visceral Metastases: The disease can also spread to distant skin, subcutaneous tissue, muscle, or non-regional lymph nodes. These sites can be difficult to detect on physical exam, especially if small or deep, but are readily identified by metabolic imaging.

Bone Metastases: While less common than in cancers like breast or prostate, melanoma can metastasize to the bone. Identifying skeletal involvement is crucial as it can be a source of significant morbidity, including pain and pathologic fractures, and may require palliative radiation or specific bone-targeted agents.

Why Is Whole-Body FDG-PET/CT Usually Appropriate for Initial Staging?

For patients with high-risk primary melanoma or confirmed nodal involvement, the ACR designates `FDG-PET/CT whole body` as Usually appropriate. This recommendation is based on the modality’s superior ability to perform a comprehensive, single-session assessment for distant metastatic disease, which is present in a significant minority of these patients at diagnosis.

The primary advantage of PET/CT is its high sensitivity for detecting metabolically active melanoma deposits throughout the body. It combines functional data from Positron Emission Tomography (PET), which highlights areas of high glucose uptake typical of tumors, with the anatomic localization provided by Computed Tomography (CT). This fusion is highly effective for identifying occult metastases in lymph nodes, soft tissues, and visceral organs that may be missed by anatomic imaging alone. Its whole-body nature is a key strength, as it can uncover unexpected sites of disease that would not have been included in standard regional CT scans.

Alternative modalities are rated lower for this specific staging scenario. For instance, a `CT chest with IV contrast` and a `CT abdomen and pelvis with IV contrast` are rated May be appropriate. While these can detect larger metastases in the lungs and abdominal organs, they lack the metabolic information of PET and have lower sensitivity for small-volume disease, particularly in non-enlarged lymph nodes or subcutaneous tissues. Similarly, a `Bone scan whole body` is Usually not appropriate because FDG-PET/CT is more sensitive for detecting osseous metastases from melanoma.

The main trade-off with PET/CT is the radiation exposure, which is relatively high (`adult_rrl=☢☢☢☢ 10-30 mSv`). However, in the context of staging a high-risk malignancy where the findings will directly guide potentially curative or life-prolonging therapy, the diagnostic benefit is considered to far outweigh the radiation risk.

What’s Next After FDG-PET/CT? Downstream Workflow

The results of the staging FDG-PET/CT will direct the subsequent clinical pathway. The findings create clear decision points for the multidisciplinary tumor board, which typically includes surgical oncology, medical oncology, dermatology, and radiation oncology.

If the PET/CT is negative for distant metastases: The patient is confirmed to have Stage III disease (regional nodal involvement without distant spread). The focus of treatment will be on controlling the regional disease and reducing the risk of future recurrence. This typically involves consideration of complete lymph node dissection, adjuvant systemic therapy (such as immunotherapy or targeted therapy), and potentially adjuvant radiation to the nodal basin.

If the PET/CT is positive for distant metastases: The patient is upstaged to Stage IV. This finding fundamentally alters the treatment plan. The primary goal shifts from regional control to systemic disease management. While surgery or radiation may still be used for palliative control of specific symptomatic lesions, the cornerstone of treatment becomes systemic therapy. A biopsy of an accessible metastatic lesion may be performed to confirm the diagnosis and provide tissue for molecular testing (e.g., for BRAF mutations) to guide targeted therapy selection.

If the PET/CT shows indeterminate findings: Occasionally, a finding may be equivocal (e.g., mild FDG uptake in a non-enlarged node or an adrenal nodule). In these cases, further characterization is necessary. This may involve a dedicated anatomic imaging study, such as an `MRI abdomen and pelvis without and with IV contrast` (rated May be appropriate) to better evaluate a liver or adrenal lesion, or a short-interval follow-up scan to assess for change. Biopsy of the indeterminate site remains the gold standard if it is safely accessible and the result would change management.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can complicate the staging process for high-risk melanoma. First, be aware of physiologic FDG uptake; areas like the brain, heart, kidneys, and brown fat can show intense activity and be mistaken for malignancy by an inexperienced reader. Second, inflammatory or infectious processes can also be FDG-avid, creating false-positive results. A detailed clinical history is essential for the interpreting radiologist. Third, avoid ordering separate CT scans of the chest, abdomen, and pelvis when a PET/CT is indicated and available, as this leads to redundant radiation exposure and provides less sensitive information. Finally, remember that PET/CT has limited sensitivity for small brain metastases. If the patient has neurologic symptoms, a dedicated brain MRI is the appropriate next step, regardless of the PET/CT findings. If the PET/CT report is ambiguous or contradicts the clinical picture, direct consultation with the nuclear medicine physician or radiologist is crucial for clarification and to determine the best next step.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a broader view of imaging across all clinical situations in this topic, or to explore the tools used to make these recommendations, the following resources are valuable.

Frequently Asked Questions

Is a brain MRI necessary for initial staging in every patient with high-risk melanoma?

No, not for every patient. According to the ACR, a brain MRI is rated ‘May be appropriate’ for this scenario. It is typically reserved for patients who present with neurologic signs or symptoms (e.g., headache, seizure, focal weakness) or for those with a very high disease burden (e.g., numerous distant metastases found on PET/CT). For asymptomatic patients, whole-body PET/CT is the standard initial staging study.

What if my patient has a contraindication to CT contrast, like a severe allergy or renal failure?

The CT portion of a PET/CT is often performed without intravenous contrast for attenuation correction and anatomic localization. If a diagnostic-quality, contrast-enhanced CT is needed for a specific area of concern (like the liver), and the patient has a contraindication, an alternative study like MRI may be considered. For example, an ‘MRI abdomen and pelvis without IV contrast’ is also rated ‘May be appropriate’ and can provide excellent detail of solid organs without contrast.

My patient’s sentinel lymph node biopsy was positive. Why do I need a PET/CT instead of just proceeding to lymph node dissection?

A positive sentinel node confirms regional (Stage III) disease, but it also significantly increases the risk of having occult distant (Stage IV) disease. A PET/CT is performed to rule out these distant metastases. Finding distant disease would fundamentally change the treatment plan from primarily surgical/regional management to systemic therapy, potentially avoiding the morbidity of a complete lymph node dissection that would not be curative in the setting of Stage IV disease.

How should I handle a finding of an isolated, FDG-avid adrenal nodule on the staging PET/CT?

An isolated FDG-avid adrenal nodule is a common indeterminate finding. While it can represent a metastasis, benign adrenal adenomas can also show mild to moderate FDG uptake. The next step is typically further characterization with a dedicated imaging study. An adrenal-protocol CT or an MRI with chemical shift imaging can often differentiate a benign adenoma from a metastasis. If the finding remains equivocal and would alter the patient’s stage and treatment plan, a biopsy may be necessary.

Does this guidance apply to ocular melanoma?

No, this guidance is for cutaneous and muco-cutaneous melanoma. Ocular melanoma has a different pattern of metastatic spread, most commonly to the liver. The imaging workup for initial staging of ocular melanoma is a separate clinical scenario with its own set of ACR recommendations, which typically prioritizes liver-specific imaging like MRI of the abdomen.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026